---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-007957"
form_type: "8-K"
ticker: null
cik: "0001711933"
company_name: "Akoya Biosciences, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:28:41.487883+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Akoya Q1 revenue falls 14% to $18.4M; cuts FY2024 revenue guidance to $104-$112M

## Summary
- Revenue $18.4M, down 14% YoY; GAAP operating loss $21.6M (non-GAAP $15.2M).
- GAAP gross margin 46% (57% non-GAAP adjusted) from legacy instrument write-off.
- Installed base up 22% to 1,213; 1,307 publications +52% YoY.
- Cash $61.6M; reaffirms target of operating cash flow breakeven by year-end 2024.
- Cites capex pressure, deferred pharma lab revenue, and reagent fulfillment delays.

## SEC filing metadata
- accession: 0001558370-24-007957
- form_type: 8-K
- cik: 0001711933
- company_name: Akoya Biosciences, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711933/000155837024007957/0001558370-24-007957-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711933/000155837024007957/akya-20240513x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-007957
- JSON: https://secwatch.observer/filing/0001558370-24-007957.json
- Plain text: https://secwatch.observer/filing/0001558370-24-007957.txt

## Key facts
- Earnings Releases
  Akoya Biosciences, Inc. reported the first quarter ending March 31, 2024 results: revenue $18.4 million. Guidance lowered.
  - Period: the first quarter ending March 31, 2024
  - Revenue: $18.4 million
  - Guidance: lowered
  - Result: reported results
  source text: (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2024. ​ Business Highlights ​ ● Revenue was $18.4 million in the first quarter of 2024, compared to $21.4 million in the prior year period; a decrease of 14%. Reagents and services revenue continued to increase. ● Akoya announced the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711933/000155837024007957/0001558370-24-007957-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.